Fierce Biotech

Subscribe to Fierce Biotech feed
Updated: 3 hours 25 min ago

FDA adds Class I tag to Dräger’s recall of 36K ventilator filters

Wed, 06/22/2022 - 08:53
FDA adds Class I tag to Dräger’s recall of 36K ventilator filters apark Wed, 06/22/2022 - 11:53

GE Healthcare debuts wireless, wearable hospital patient monitor

Wed, 06/22/2022 - 07:24
GE Healthcare debuts wireless, wearable hospital patient monitor chale Wed, 06/22/2022 - 10:24

Medtronic reinforces spine surgery portfolio with FDA nod for ligament-augmenting implant

Wed, 06/22/2022 - 07:23
Medtronic reinforces spine surgery portfolio with FDA nod for ligament-augmenting implant apark Wed, 06/22/2022 - 10:23

Appetite for allergies: Alladapt banks $119M to push immunotherapy through trials

Wed, 06/22/2022 - 07:03
Appetite for allergies: Alladapt banks $119M to push immunotherapy through trials jwaldron Wed, 06/22/2022 - 10:03

Beacon of Hope: Novartis commits $17.7M to set up clinical trial centers in historically Black medical schools

Wed, 06/22/2022 - 05:57
Beacon of Hope: Novartis commits $17.7M to set up clinical trial centers in historically Black medical schools jwaldron Wed, 06/22/2022 - 08:57

Frying pan, meet fire: Athira flunks Alzheimer's trial to pile on the pain ahead of phase 3 data drop

Wed, 06/22/2022 - 03:57
Frying pan, meet fire: Athira flunks Alzheimer's trial to pile on the pain ahead of phase 3 data drop ntaylor Wed, 06/22/2022 - 06:57

Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact

Wed, 06/22/2022 - 00:41
Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact ntaylor Wed, 06/22/2022 - 03:41

CRISPR Tx's Innovation Day dragged down by multiple myeloma replacement, lackluster results in kidney cancer

Tue, 06/21/2022 - 20:37
CRISPR Tx's Innovation Day dragged down by multiple myeloma replacement, lackluster results in kidney cancer gmasson Tue, 06/21/2022 - 23:37

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Tue, 06/21/2022 - 17:57
Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push aarmstrong Tue, 06/21/2022 - 20:57

Patient empowerment goes from 'trend to permanent movement' as cancer trial interest grows

Tue, 06/21/2022 - 16:27
Patient empowerment goes from 'trend to permanent movement' as cancer trial interest grows aarmstrong Tue, 06/21/2022 - 19:27

9 Meters’ celiac drug doesn’t measure up in phase 3

Tue, 06/21/2022 - 10:20
9 Meters’ celiac drug doesn’t measure up in phase 3 gmasson Tue, 06/21/2022 - 13:20

Human Longevity seeks new life with proposed SPAC deal

Tue, 06/21/2022 - 09:22
Human Longevity seeks new life with proposed SPAC deal chale Tue, 06/21/2022 - 12:22

PathAI co-founder Khosla carves a new path as CTO of Iterative Scopes

Tue, 06/21/2022 - 09:11
PathAI co-founder Khosla carves a new path as CTO of Iterative Scopes apark Tue, 06/21/2022 - 12:11

Enzyme inhibitor could counter bad 'seeds' that let leukemia bounce back

Tue, 06/21/2022 - 07:52
Enzyme inhibitor could counter bad 'seeds' that let leukemia bounce back jwaldron Tue, 06/21/2022 - 10:52

Bioventus reworks $450M CartiHeal acquisition after scrapping original debt financing plan

Tue, 06/21/2022 - 07:14
Bioventus reworks $450M CartiHeal acquisition after scrapping original debt financing plan apark Tue, 06/21/2022 - 10:14

Proofpilot, Greater Gift team on research diversity initiative

Tue, 06/21/2022 - 06:42
Proofpilot, Greater Gift team on research diversity initiative aarmstrong Tue, 06/21/2022 - 09:42

Merck's next-gen pneumococcal vaccine slated for July phase 3 after two-part win

Tue, 06/21/2022 - 05:02
Merck's next-gen pneumococcal vaccine slated for July phase 3 after two-part win jwaldron Tue, 06/21/2022 - 08:02

Lyme-light: Pfizer triggers surge in Valneva’s stock with €91M investment to support phase 3 vaccine trial

Tue, 06/21/2022 - 04:40
Lyme-light: Pfizer triggers surge in Valneva’s stock with €91M investment to support phase 3 vaccine trial ntaylor Tue, 06/21/2022 - 07:40

Hot on Alnylam’s heels, AstraZeneca racks up phase 3 win for Ionis-partnered rare disease drug

Tue, 06/21/2022 - 02:43
Hot on Alnylam’s heels, AstraZeneca racks up phase 3 win for Ionis-partnered rare disease drug ntaylor Tue, 06/21/2022 - 05:43

Decentralized trials an agile solution for cancer R&D, says Science 37

Fri, 06/17/2022 - 12:12
Decentralized trials an agile solution for cancer R&D, says Science 37 aarmstrong Fri, 06/17/2022 - 15:12